2. Signaling Pathways
  3. Immunology/Inflammation
  4. Glycoprotein VI

Glycoprotein VI

GPVI

Glycoprotein VI (GPVI) is a membrane glycoprotein unique to platelets and has been identified as a physiological receptor for collagen. Damage to a vessel wall exposes the subendothelial component collagen to platelets in the blood flow. Interaction of platelets with collagen via the receptor GPVI results in platelet activation and adhesion--the processes that are essential for thrombus formation. On the platelet surface, GPVI is present as a complex with the homodimeric Fc receptor y-chain (FcRgamma with a possible stoichiometry of two GPVI molecules and one FcRgamma dimer). When collagen binds to GPVI, a platelet activation cascade is initiated by tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif of FcRgamma and this phosphorylation induces the formation of a large complex composed from many signal-transducing proteins. In flow adhesion experiments that closely approximate physiological conditions, GPVI is essential for the formation of large platelet aggregates on collagen.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99013
    Codrituzumab
    		Inhibitor
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
    Codrituzumab
  • HY-125053A
    Batifiban TFA
    		Antagonist 99.58%
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
    Batifiban TFA
  • HY-144390
    (S)-S007-1558
    		99.78%
    (S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM.
    (S)-S007-1558
  • HY-115912
    GPVI antagonist 3
    		Antagonist
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
    GPVI antagonist 3
  • HY-115911
    GPVI antagonist 2
    		Antagonist
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent.
    GPVI antagonist 2
  • HY-P990840
    Anti-GPC3 Antibody (YP7)
    		Inhibitor
    Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-GPC3 Antibody (YP7)
  • HY-125615
    DMP 728 methanesulfonate
    		Antagonist
    DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries.
    DMP 728 methanesulfonate
Cat. No. Product Name / Synonyms Application Reactivity